Shanghai Haohai Biological Technology Co., Ltd. Class A

As of June 30, 2026, Shanghai Haohai Biological Technology Co., Ltd. Class H carries a market capitalization of 796.23M, placing it among publicly traded companies globally. Its enterprise value stands at 564.54M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Shanghai Haohai Biological Technology Co., Ltd. Class H's next confirmed earnings release is scheduled for October 23, 2026.

As of June 30, 2026, Shanghai Haohai Biological Technology Co., Ltd. Class H has 476.78M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Shanghai Haohai Biological Technology Co., Ltd. Class H maintains a current ratio of 3.49, meaning it holds 3.5x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on September 3, 2026, Shanghai Haohai Biological Technology Co., Ltd. Class H's stock has declined approximately 38.78% over the past 52 weeks. The 50-day moving average sits at 1.76, while the 200-day moving average is 2.32.

As of June 30, 2026, Shanghai Haohai Biological Technology Co., Ltd. Class H holds 308.87M in cash and equivalents against 57.18M in total debt, resulting in a net debt position of -246.61M. Total book value stands at 684.16M, with working capital of 307.91M providing operational flexibility.

Shanghai Haohai Biological Technology Co., Ltd. Class H's most recent stock split took place on June 6, 2024 with a 5:7 split ratio.